Abstract
This contribution provides analyses of four ethically problematic issues in genetic risk assessment and management. First, should we require a positive risk-benefit balance for each concerned individual, or is it sufficient that the total sum of benefits outweighs the total sum of risks? Secondly, should sensitive groups have special protection, and in that case with what types of measures? Thirdly, what types of measures should be taken to protect against the risks associated with teratogenic, embryotoxic and foetotoxic agents? Fourthly, how should we deal with the new issues relating to equity and to group-based risk assessment that genomic medicine gives rise to?
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
